Penicillamine is used mainly in treating rheumatoid arthritis but it is also used in Wilson's disease and cystinuria. Its place in treating cryptogenic fibrosing alveolitis and histiocytosis X is being investigated.
The common side-effects are nausea, vomiting, rashes, bone marrow depression, and albuminuria. A rare side-effect is Goodpasture's syndrome.'
One case of diffuse alveolitis has also been recorded in a patient with rheumatoid arthritis who had taken penicillamine for a year. In May 1978 she developed abdominal pain and diarrhoea and was admitted to hospital. Examination showed pallor and active polyarthritis but no other abnormality. The haemoglobin was 9 7 g/dl with a low serum iron and normal iron binding capacity, the white blood count was 9 4x109/l (9400/mm3) with a normal differential count, the ESR was 130mm in one hour (Westergren), and the alkaline phosphatase was 265 units/l. There was a slight reduction in serum albumin and an increase in alpha-2 and gamma globulins. The urea, electrolytes, and chest radiograph were normal.
The pain and diarrhoea settled and she was started on d-penicillamine 125 mg daily on 11 May. She was discharged on this together with flubriprofen, diflunisal, Ferrograd C, and indomethacin suppositories. The It seems probable that the lung disease was caused by penicillamine. Fairly rapid improvement occurred when the drug was stopped and the other medicaments continued. There was nothing to suggest infection and the patient was not exposed to organic antigens. It is possible that equally good clearing would have occurred even without the later use of corticosteroids. She still has somc restriction of ventilation but there were no readings before this episode. There is no clinical evidence of rheumatoid fibrosing alveolitis.
The other published case2 was described as having diffuse alveolitis. Blood eosinophilia was not recorded and there was rapid improvement when penicillamine was stopped. At three months the lung function tests had returned to normal except for a reduced transfer factor. The reaction in our case was also at alveolar level and it is probably best classified as subcute pulmonary eosinophilia. 
